• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

B-RafV600E通过调控DNA甲基转移酶1来抑制钠碘同向转运体的表达。

B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1.

作者信息

Choi Yong Won, Kim Hyun-Ju, Kim Young Hwa, Park So Hyun, Chwae Yong Jun, Lee Jeonghun, Soh Euy Young, Kim Jang-Hee, Park Tae Jun

机构信息

Department of Biochemistry and Molecular Biology, Ajou University School of Medicine, Suwon, Korea.

Department of Microbiology, Ajou University School of Medicine, Suwon, Korea.

出版信息

Exp Mol Med. 2014 Nov 7;46(11):e120. doi: 10.1038/emm.2014.68.

DOI:10.1038/emm.2014.68
PMID:25378232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4261912/
Abstract

B-RafV600E mutant is found in 40-70% of papillary thyroid carcinoma (PTC) and has an important role in the pathogenesis of PTC. The sodium iodide symporter (NIS) is an integral plasma membrane glycoprotein that mediates active iodide transport into the thyroid follicular cells, and B-RafV600E has been known to be associated with the loss of NIS expression. In this study, we found that B-RafV600E inhibited NIS expression by the upregulation of its promoter methylation, and that specific regions of CpG islands of NIS promoter in B-RafV600E harboring PTC were highly methylated compared with surrounding normal tissue. Although DNA methyltransferase 3a and 3b (DNMT3a,3b) were not increased by B-RafV600E, DNMT1 expression was markedly upregulated in PTC and B-RafV600E expressing thyrocytes. Furthermore, DNMT1 expression was upregulated by B-RafV600E induced NF-κB activation. These results led us to conclude that NIS promoter methylation, which was induced by B-RafV600E, is one of the possible mechanisms involved in NIS downregulation in PTC.

摘要

在40%-70%的甲状腺乳头状癌(PTC)中发现了B-RafV600E突变体,其在PTC的发病机制中起重要作用。碘化钠同向转运体(NIS)是一种完整的质膜糖蛋白,介导碘离子主动转运进入甲状腺滤泡细胞,已知B-RafV600E与NIS表达缺失有关。在本研究中,我们发现B-RafV600E通过上调其启动子甲基化来抑制NIS表达,并且与周围正常组织相比,携带B-RafV600E的PTC中NIS启动子的CpG岛特定区域高度甲基化。尽管B-RafV600E不会增加DNA甲基转移酶3a和3b(DNMT3a、3b),但在PTC和表达B-RafV600E的甲状腺细胞中,DNMT1表达明显上调。此外,B-RafV600E诱导的NF-κB激活会上调DNMT1表达。这些结果使我们得出结论,B-RafV600E诱导的NIS启动子甲基化是PTC中NIS下调的可能机制之一。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d1/4261912/20ad50feb0ae/emm201468f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d1/4261912/79a2b1a77a9c/emm201468f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d1/4261912/8dbb665ac249/emm201468f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d1/4261912/0b70d8ec8493/emm201468f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d1/4261912/4ca8b3a38dfc/emm201468f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d1/4261912/20ad50feb0ae/emm201468f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d1/4261912/79a2b1a77a9c/emm201468f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d1/4261912/8dbb665ac249/emm201468f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d1/4261912/0b70d8ec8493/emm201468f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d1/4261912/4ca8b3a38dfc/emm201468f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d1/4261912/20ad50feb0ae/emm201468f5.jpg

相似文献

1
B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1.B-RafV600E通过调控DNA甲基转移酶1来抑制钠碘同向转运体的表达。
Exp Mol Med. 2014 Nov 7;46(11):e120. doi: 10.1038/emm.2014.68.
2
TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6.促甲状腺激素(TSH)信号通过调节双特异性磷酸酶6(DUSP6)克服甲状腺乳头状癌发生过程中B-RafV600E诱导的衰老。
Neoplasia. 2014 Dec;16(12):1107-20. doi: 10.1016/j.neo.2014.10.005.
3
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.BRAFV600E突变而非RET/PTC重排与甲状腺乳头状癌中甲状腺过氧化物酶和钠碘同向转运体基因的低表达相关。
Endocr Relat Cancer. 2008 Jun;15(2):511-20. doi: 10.1677/ERC-07-0130.
4
The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.BRAFV600E致癌基因诱导转化生长因子β分泌,导致甲状腺癌中钠碘同向转运体受抑制并增加恶性程度。
Cancer Res. 2009 Nov 1;69(21):8317-25. doi: 10.1158/0008-5472.CAN-09-1248. Epub 2009 Oct 27.
5
Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.DNMT3A 改变在中东地区甲状腺滤泡状癌中的预后意义。
Eur J Cancer. 2019 Aug;117:133-144. doi: 10.1016/j.ejca.2019.05.025. Epub 2019 Jul 4.
6
Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells.人钠/碘同向转运体基因启动子在甲状腺乳头状癌细胞系和正常甲状腺细胞中的差异调控
Endocrinology. 2001 Aug;142(8):3369-79. doi: 10.1210/endo.142.8.8344.
7
Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.BRAF(V600E)突变对甲状腺乳头状癌中钠/碘同向转运体表达的影响。
J Huazhong Univ Sci Technolog Med Sci. 2016 Feb;36(1):77-81. doi: 10.1007/s11596-016-1545-3. Epub 2016 Feb 3.
8
NADPH Oxidase NOX4 Is a Critical Mediator of BRAF-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas.烟酰胺腺嘌呤二核苷酸磷酸氧化酶NOX4是BRAF诱导的甲状腺乳头状癌中钠/碘同向转运体下调的关键介质。
Antioxid Redox Signal. 2017 May 20;26(15):864-877. doi: 10.1089/ars.2015.6616. Epub 2016 Aug 22.
9
The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.经典型乳头状甲状腺癌中碘化钠转运体与BRAF(V600E)突变的相关性
Ann Diagn Pathol. 2016 Jun;22:58-62. doi: 10.1016/j.anndiagpath.2016.04.002. Epub 2016 Apr 9.
10
Hypermethylation of a New Distal Sodium/Iodide Symporter (NIS) enhancer (NDE) is associated with reduced NIS expression in thyroid tumors.一种新的远端钠/碘转运体(NIS)增强子(NDE)的高甲基化与甲状腺肿瘤中NIS表达降低有关。
J Clin Endocrinol Metab. 2014 Jun;99(6):E944-52. doi: 10.1210/jc.2013-1450. Epub 2014 Jan 16.

引用本文的文献

1
Hypoxia Inhibitor Improves Iodine Uptake Disorder in Thyroid Cancer Through the hsa_circ_0023990/miR-448/DNMT1/NIS Axis.缺氧抑制剂通过hsa_circ_0023990/miR-448/DNMT1/钠碘同向转运体轴改善甲状腺癌碘摄取障碍
Cancer Sci. 2025 Aug;116(8):2113-2124. doi: 10.1111/cas.70102. Epub 2025 May 19.
2
Vitamin C in the Management of Thyroid Cancer: A Highway to New Treatment?维生素C在甲状腺癌治疗中的应用:通往新疗法之路?
Antioxidants (Basel). 2024 Oct 15;13(10):1242. doi: 10.3390/antiox13101242.
3
Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.

本文引用的文献

1
Molecular pathogenesis and mechanisms of thyroid cancer.甲状腺癌的分子发病机制及机制。
Nat Rev Cancer. 2013 Mar;13(3):184-99. doi: 10.1038/nrc3431.
2
Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression.甲状腺良、恶性肿瘤组织中钠碘转运体(NIS)启动子甲基化水平与 NIS 低表达的关系。
Endocrine. 2013 Feb;43(1):225-9. doi: 10.1007/s12020-012-9779-8. Epub 2012 Sep 1.
3
The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.
联合伏立诺他和氯喹抑制钠碘同向转运体内吞作用并增强放射性核素摄取体内。
Clin Cancer Res. 2024 Apr 1;30(7):1352-1366. doi: 10.1158/1078-0432.CCR-23-2043.
4
Tumor Microbial Communities and Thyroid Cancer Development-The Protective Role of Antioxidant Nutrients: Application Strategies and Future Directions.肿瘤微生物群落与甲状腺癌发展——抗氧化营养素的保护作用:应用策略与未来方向
Antioxidants (Basel). 2023 Oct 23;12(10):1898. doi: 10.3390/antiox12101898.
5
Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment.甲状腺癌治疗中的表观遗传靶点及其抑制剂
Pharmaceuticals (Basel). 2023 Apr 7;16(4):559. doi: 10.3390/ph16040559.
6
Association of DNA Promoter Methylation and Mutation in Thyroid Cancer.甲状腺癌中 DNA 启动子甲基化与突变的相关性。
Curr Oncol. 2023 Mar 2;30(3):2978-2996. doi: 10.3390/curroncol30030227.
7
CpG island status as an epigenetic alteration for NIS promoter in thyroid neoplasms; a cross-sectional study with a systematic review.甲状腺肿瘤中NIS启动子的CpG岛状态作为一种表观遗传改变;一项系统评价的横断面研究
Cancer Cell Int. 2022 Oct 11;22(1):310. doi: 10.1186/s12935-022-02720-w.
8
Redox Homeostasis in Thyroid Cancer: Implications in Na/I Symporter (NIS) Regulation.甲状腺癌中的氧化还原平衡:对钠/碘同向转运体(NIS)调节的影响。
Int J Mol Sci. 2022 May 30;23(11):6129. doi: 10.3390/ijms23116129.
9
Comprehensive Analysis of the Prognosis and Drug Sensitivity of Differentiation-Related lncRNAs in Papillary Thyroid Cancer.甲状腺乳头状癌中分化相关长链非编码RNA的预后及药物敏感性综合分析
Cancers (Basel). 2022 Mar 7;14(5):1353. doi: 10.3390/cancers14051353.
10
Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.分化型甲状腺癌中放射性碘难治性的分子机制:由于信号通路活性改变和钠碘同向转运体(NIS)的细胞内定位改变导致NIS表达受损。
Theranostics. 2021 Apr 15;11(13):6251-6277. doi: 10.7150/thno.57689. eCollection 2021.
钠碘转运体(NIS):调控与靶向治疗癌症的策略。
Pharmacol Ther. 2012 Sep;135(3):355-70. doi: 10.1016/j.pharmthera.2012.06.007. Epub 2012 Jun 29.
4
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.小分子 MAPK 抑制剂恢复条件性 BRAF 激活的小鼠甲状腺癌中的碘摄取。
J Clin Invest. 2011 Dec;121(12):4700-11. doi: 10.1172/JCI46382. Epub 2011 Nov 21.
5
Global cancer statistics.全球癌症统计数据。
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
6
The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.BRAF 突变可预测甲状腺微小乳头状癌侵袭性临床病理特征。
Ann Surg Oncol. 2010 Dec;17(12):3294-300. doi: 10.1245/s10434-010-1129-6. Epub 2010 Oct 15.
7
The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.BRAFV600E致癌基因诱导转化生长因子β分泌,导致甲状腺癌中钠碘同向转运体受抑制并增加恶性程度。
Cancer Res. 2009 Nov 1;69(21):8317-25. doi: 10.1158/0008-5472.CAN-09-1248. Epub 2009 Oct 27.
8
Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.高侵袭性甲状腺微小乳头状癌中BRAF(V600E)突变状态的差异分析
Ann Surg Oncol. 2009 Feb;16(2):240-5. doi: 10.1245/s10434-008-0233-3. Epub 2008 Nov 26.
9
Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.人甲状腺组织中碘代谢基因的表达:年龄和BRAFV600E突变依赖性的证据。
Clin Endocrinol (Oxf). 2009 Apr;70(4):629-35. doi: 10.1111/j.1365-2265.2008.03376.x. Epub 2008 Aug 15.
10
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.BRAFV600E突变而非RET/PTC重排与甲状腺乳头状癌中甲状腺过氧化物酶和钠碘同向转运体基因的低表达相关。
Endocr Relat Cancer. 2008 Jun;15(2):511-20. doi: 10.1677/ERC-07-0130.